Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919623 | 0.83 | DPP4 (0.35) | NPSR1ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL14218899 | 0.83 | DPP4 (0.35) | NPSR1ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL12696686 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MEN1KMT2ATSHRL3MBTL1 | |
| SCHEMBL20285870 | 0.81 | NPSR1 (0.34) | NPSR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL19348571 | 0.81 | NPSR1 (0.34) | NPSR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL11303192 | 0.80 | CYP1A2 (0.43) | NPSR1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL25741024 | 0.80 | CYP1A2 (0.43) | NPSR1ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL25253736 | 0.79 | EPHX2 (0.34) | NPSR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL21576490 | 0.79 | NPSR1 (0.33) | NPSR1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20690392 | 0.79 | NPSR1 (0.33) | NPSR1ALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20170267661-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2017-09-21 | — | — | US | disclosed |
| WO-2017161269-A1 | INHIBITORS OF RET RECEPTOR TYROSINE KINASES | BLUEPRINT MEDICINES CORPORATION (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159517-A1 | CHROMANE AMIDINE MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TCOF1, SLC10A2, PAM | NPSR1 2104/4885ALDH1A1 4179/4885MEN1 77/4885 |
| US-20170267661-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | NPSR1 3593/4885ALDH1A1 3153/4885MEN1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.